1. Home
  2. VMD vs DMAC Comparison

VMD vs DMAC Comparison

Compare VMD & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Viemed Healthcare Inc.

VMD

Viemed Healthcare Inc.

HOLD

Current Price

$7.34

Market Cap

280.4M

Sector

N/A

ML Signal

HOLD

Logo DiaMedica Therapeutics Inc.

DMAC

DiaMedica Therapeutics Inc.

HOLD

Current Price

$8.42

Market Cap

441.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VMD
DMAC
Founded
2006
2000
Country
United States
United States
Employees
N/A
28
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
280.4M
441.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
VMD
DMAC
Price
$7.34
$8.42
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$15.50
AVG Volume (30 Days)
158.9K
584.7K
Earning Date
11-05-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
35.92
N/A
EPS
0.34
N/A
Revenue
$254,794,000.00
N/A
Revenue This Year
$20.05
N/A
Revenue Next Year
$17.44
N/A
P/E Ratio
$21.85
N/A
Revenue Growth
18.89
N/A
52 Week Low
$5.93
$3.19
52 Week High
$8.62
$10.42

Technical Indicators

Market Signals
Indicator
VMD
DMAC
Relative Strength Index (RSI) 61.27 54.27
Support Level $7.31 $8.00
Resistance Level $7.68 $8.73
Average True Range (ATR) 0.20 0.67
MACD 0.03 -0.12
Stochastic Oscillator 69.77 27.24

Price Performance

Historical Comparison
VMD
DMAC

About VMD Viemed Healthcare Inc.

Viemed Healthcare Inc is a provider of medical equipment and home therapy to patients with respiratory disease, oxygen problems, sleep apnea and PAP treatment. The company also provides services such as respiratory disease management, neuromuscular care, in-home sleep testing and sleep apnea treatment, oxygen therapy, respiratory equipment rentals, and healthcare staffing services. The company generates majority its revenue from medical equipment rental, sales and supply.

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

Share on Social Networks: